BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jan 10, 2005
 |  BioCentury  |  Emerging Company Profile

elbion: Specificity rules

Many side effects of drugs are caused by insufficient specificity for a certain target. This shortcoming provides opportunities for companies with insights into chemistry and target architecture to work in indications already populated by established drugs or where it has been difficult to develop drugs against attractive targets. elbion AG claims it has sufficient expertise to come up with alternatives to benzodiazepines and PDE-4 inhibitors in CNS and respiratory indications.

elbion is the result of a 2002 management buyout from Asta Medica, a unit of Degussa AG (FSE:DGX, Frankfurt, Germany), when DGX had decided to focus on fine chemicals. The newco inherited drug discovery and research in CNS, respiratory and inflammatory diseases, along with a small molecule compound library, a drug discovery engine and medicinal and computational chemistry.

Some projects were already in the clinic, and shortly after its founding, elbion was able to close a partnership in respiratory...

Read the full 729 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >